Company Sisram Medical Ltd

Equities

1696

IL0011418113

Advanced Medical Equipment & Technology

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
3.54 ^HKD	+7.93%		+13.46%	-32.70%

Mar. 21	Sisram Medical’s Profit Down in Fiscal 2023	MT
Mar. 20	Sisram Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Business Summary

Sisram Medical Ltd is an investment holding company principally engaged in the design, development, manufacture and distribution of energy cosmetic medicine and minimally invasive medical cosmetic treatment systems. The Company has a comprehensive medical cosmetic equipment portfolio, including medical beauty product line and life beauty product line, can be used for noninvasive medical cosmetic treatment, such as hair removal, rejuvenation, skin care, vascular treatment and pigmented lesions treatment, removal of tattoos, acne Treatment, fat reduction, body shaping and firming. The Company's medical cosmetic equipment can also be used for minimally invasive medical cosmetic treatment, such as private beauty treatment, laser liposuction, treatment of varicose veins and treatment of hyperhidrosis. The company sells its products in domestic and foreign markets.

Number of employees: 1,080

Sales per Business

HKD in Million	2021	Weight	2022	Weight	Delta
Medical Aesthetics 86.6 %	2,009	87.8 %	2,403	86.6 %	+19.59%
Services and Other 5.6 %	121	5.3 %	155	5.6 %	+28.36%
Dental 5.2 %	108	4.7 %	146	5.2 %	+35.39%
Injectables 2.6 %	50	2.2 %	72	2.6 %	+44.99%

Sales per region

HKD in Million	2021	Weight	2022	Weight	Delta
North America 40.5 %	871	38.1 %	1,125	40.5 %	+29.18%
Asia Pacific 27.7 %	662	29.0 %	768	27.7 %	+15.94%
Europe 16.5 %	403	17.6 %	457	16.5 %	+13.23%
Middle East and Africa 10.3 %	239	10.5 %	286	10.3 %	+19.61%
Latin America 5.0 %	111	4.9 %	140	5.0 %	+25.32%

Managers

Managers	Title	Age	Since
Lior Moshe Dayan CEO	Chief Executive Officer	54	17-06-05
Nikol Lev CTO	Chief Tech/Sci/R&D Officer	-	-
Itay Meir CTO	Chief Tech/Sci/R&D Officer	-	-
Ran Ezioni COO	Chief Operating Officer	57	18-03-31
Yosef Lepzelter CTO	Chief Tech/Sci/R&D Officer	68	11-03-31
Tal Burgan Rosen SAM	Sales & Marketing	-	-
Qianli Fang SEC	Corporate Secretary	30	22-01-09
Anat Kenan HRO	Human Resources Officer	65	-
Avraham Farbstein PRN	Corporate Officer/Principal	69	18-03-18
Doron Yannai HRO	Human Resources Officer	63	14-01-31

Members of the board

Members of the board	Title	Age	Since
Heung Sang Fong BRD	Director/Board Member	64	16-12-31
Yi Fang Wu BRD	Director/Board Member	54	16-10-16
Lior Moshe Dayan CEO	Chief Executive Officer	54	17-06-05
Chi Fung Chan BRD	Director/Board Member	45	17-08-29
Yi Liu CHM	Chairman	48	16-04-13
Jenny Chen BRD	Director/Board Member	44	16-12-31
Kai Yu Liu BRD	Director/Board Member	54	17-08-29
Rong Li Feng BRD	Director/Board Member	49	20-08-19

Share class

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	468,343,092	133,159,792 ( 28.43 %)	0	28.43 %

Shareholders

Name	Equities	%	Valuation
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 71.42 %	334,504,800	71.42 %	151 M $
China Asset Management Co., Ltd. 0.3587 %	1,680,000	0.3587 %	757 730 $
China Southern Asset Management Co., Ltd. 0.3275 %	1,533,600	0.3275 %	691 700 $
Lior Moshe Dayan 0.2004 %	938,500	0.2004 %	423 292 $
Yi Liu 0.0534 %	250,000	0.0534 %	112 758 $
Guojun Bu 0.0171 %	80,000	0.0171 %	36 082 $
Guardians of New Zealand Superannuation 0.0123 %	57,600	0.0123 %	25 979 $
Irish Life Investment Managers Ltd. 0.001138 %	5,332	0.001138 %	2 405 $